An Undervalued but High Uncertainty Biotech Firm
Intercept's NASH treatment could be approved years ahead of competition.
Anna Baran: We believe that Intercept, an emerging biotechnology company, is very undervalued by the market. We think that Intercept could have the first approved drug for a very serious but common liver disease known as NASH. I'll mention two points.
First, its timeline: Intercept is significantly ahead of its competitors. It just filed for approval for its drug OCA in the United States. And if the company gets priority review, it could have an approval as early as six months. This is years ahead of its competition. We predict that its competitors won't be entering the market until 2022 and 2023.
Anna Baran does not own shares in any of the securities mentioned above. Find out about Morningstar’s editorial policies.